Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

Tuberculosis Clinical Trial

Official title:

An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01311505
• Other study ID #: B3801001
• Status: Completed
• Phase: Phase 1
• First received: February 15, 2011
• Last updated: June 21, 2012
• Start date: April 2011
• Est. completion date: May 2011

Study information

• Verified date: June 2012
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Philippines: Department of Health
• Study type: Interventional

Clinical Trial Summary

This study is done to demonstrate bioequivalence of rifampicin component in Myrin© 2 Fixed-Dose Combination Tablet (each contains 75 mg isoniazid and 150 mg rifampicin, Pfizer Inc) with equivalent dose of the reference Rimactane® capsule (each contains 300 mg rifampicin, Novartis Sandoz) in healthy Filipino male subjects. This study also aims to determine the safety and tolerability of Myrin© 2 tablets and Rimactane® capsules in these subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy male subjects between the ages of 18 and 55 years, inclusive.

• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

• An informed consent document signed and dated by the subject.

• Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

• Any condition possibly affecting drug absorption (e.g., gastrectomy).

• A positive urine drug screen.

• History of regular alcohol consumption exceeding 21 drinks/week (1 drink = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor) within 6 months of screening.

• Treatment with an investigational drug within 3 months (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.

• 12-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.

• History of previous treatment for TB or is suspected of suffering from TB.

• Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal medication, herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen / paracetamol may be used at doses of less than 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.

• Blood donation of approximately 1 pint (500 ml) within 56 days prior to dosing.

• A history of hypersensitivity to any of the study medications or related substances, or to any of the ingredients used in the study drug formulations.

• Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.

• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

• Recent history of diarrhea (2 weeks).

• Recent use of oral (2 weeks) or IV (2-3 months) antibiotics to assure normal bowel flora at study start.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Drug:
• Myrin© 2 (Rifampicin + Isoniazid)
Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
• Rimactane® (Rifampicin)
One (1) capsule of Rifampicin 300 mg

Locations

Country	Name	City	State
Philippines	Pfizer Investigational Site	Dasmariñas City

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Philippines, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])	AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)	0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose	No
Primary	Maximum Observed Plasma Concentration (Cmax)		0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose	No
Secondary	Time to Reach Maximum Observed Plasma Concentration (Tmax)		0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose	No
Secondary	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-8])	AUC (0-8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-8). It is obtained from AUC (0-t) plus AUC (t-8).	0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose	No
Secondary	Plasma Decay Half-life (t1/2)	Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.	0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose	No
Secondary	Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)	AUC%extrapolated is the extrapolated area under the plasma concentration time profile following the last measured concentration. It is calculated as (AUC [0-8] minus AUC[0-10])*100/ AUC (0-8), where AUC (0-8) = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-8) and AUC(0-10) = area under the plasma concentration time-curve from zero (pre-dose) to the last quantifiable concentration.	0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose	No

External Links

•   To obtain contact information for a study center near you, click here.